MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1007/s00415-022-11103-0

Медицинская библиотека · Journal of neurology · 2022

Clinical and genetic analyses of 150 patients with paroxysmal kinesigenic dyskinesia.

Liu Xiaoli, Ke Huiyi, Qian Xiaohang, Wang Shige, Zhan Feixia, Li Ziyi, Tian Wotu, Huang Xiaojun, Zhang Bin, Cao Li

СтатьяПеревод пока не подготовлен

Аннотация

BACKGROUND

Mutations in PRRT2 and 16p11.2 microdeletion including PRRT2 have been identified as the pathogenic cause of paroxysmal kinesigenic dyskinesia (PKD).

OBJECTIVE

The objective was to investigate the clinical and genetic features of PKD and to analyze the genotype-phenotype correlation.

METHODS

We recruited PKD patients, recorded clinical manifestations, and performed PRRT2 screening in 150 PKD patients by unified PKD registration forms. Genotype-phenotype correlation analyses were conducted in probands. High-knee-exercise (HKE) tests were applied in one hundred and six patients.

RESULTS

Eight PRRT2 mutations were detected, accounting for 22.76% of the probands. Three mutations (c.649dupC, c.649delC, and c.510_513delTCTG) were already reported, while four mutations (c.252_264delCACAGACCTCAGC, c.503_504delCT, c.679C > T, and c.804C > A) were first reported. One heterozygous microdeletion of 606 kb in 16p11.2 was detected in one patient. Compared with non-PRRT2 mutation carriers, the PRRT2 mutation carriers were younger at onset, experienced longer attacks, and tended to present with complicated PKD, combined phenotypes of dystonia and chorea. 57.01% of patients could effectively induce movement disorders through the HKE test. A good response was shown in 81.93% of the patients prescribed with antiepileptic drugs. 13.54% (13/96) had abnormal EEG results.

CONCLUSIONS

PRRT2 mutations are common in patients with PKD and are significantly associated with an earlier age at onset, longer duration of attacks, a complicated form of PKD, combined phenotypes of dystonia and chorea. Patients with microdeletion of 16p11.2 may have more severe manifestations. The HKE test could contribute to the diagnosis of PKD. Carbamazepine is still the first choice for PKD patients, but individualized treatment should be formulated.

Для цитирования: Liu Xiaoli, Ke Huiyi, Qian Xiaohang, Wang Shige, Zhan Feixia, Li Ziyi, Tian Wotu, Huang Xiaojun, Zhang Bin, Cao Li. Clinical and genetic analyses of 150 patients with paroxysmal kinesigenic dyskinesia.. Journal of neurology. 2022. DOI: 10.1007/s00415-022-11103-0.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.